prism software v.8.4.2 (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
prism software v.8.4.2
Prism Software V.8.4.2, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prism+software+v%2E+8%2E4%2E2/prism+software/pmc12195285-152-27-31
Average 90 stars, based on 1 article reviews
Prism Software V.8.4.2, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prism+software+v%2E+8%2E4%2E2/prism+software/pmc12195285-152-27-31
Average 90 stars, based on 1 article reviews
prism software v.8.4.2 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Glycoproteomic and Phenotypic Elucidation of B4GALNT2 Expression Variants in the SID Histo-Blood Group System Article Snippet: For statistical analysis, nonparametric Mann–Whitney U test was performed using the Article Title: HIV Nef and Antiretroviral Therapy Have an Inhibitory Effect on Autophagy in Human Astrocytes that May Contribute to HIV-Associated Neurocognitive Disorders Article Snippet: Data were analyzed using GraphPad Article Title: SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer Article Snippet: Statistical analyses were performed using GraphPad Article Title: A novel aminohydroxy sulfonamide formulated in PEGylated liposomes with potential antitumor activity Article Snippet: Statistically significant differences (p < 0.05) were determined by one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test or by unpaired, two-tailed t-test, using Software:Article Title: Therapeutic effects of a soluble guanylate cyclase activator, BAY 60-2770, on lower urinary tract dysfunction in mice with spinal cord injury. Article Snippet: We aimed to evaluate the effects of a soluble guanylate cyclase (sGC) activator, BAY 60-2770, on neurogenic lower urinary tract dysfunction in mice with spinal cord injury (SCI).. Mice were divided into the following three groups: spinal cord intact (group A), SCI þ vehicle (group B), and SCI þ BAY 60-2770 (group C).. SCI mice underwent Th8–Th9 spinal cord transection and treatment with BAY 60-2770 (10 mg/kg/day) once daily for 2–4 wk after SCI. |